Novartis Ag (NVS) Receivables (2009 - 2025)
Novartis Ag recorded quarterly Receivables of $10.1 billion in Q4 2025, up 11.29% quarter-over-quarter from $9.1 billion in Q2 2025, and up 18.29% year-over-year from $8.5 billion in Q4 2024.
Novartis Ag's Receivables history runs 14 years deep, the most recent figure standing at $10.1 billion for Q4 2025.
- In Q4 2025, Receivables rose 18.29% year-over-year to $10.1 billion; the TTM figure through Dec 2025 stood at $10.1 billion (up 18.29% YoY), while the FY2025 annual figure was $10.1 billion, up 18.29% from the prior year.
- Receivables came in at $10.1 billion for Q4 2025 at Novartis Ag, up from $9.1 billion in the prior quarter.
- In the past five years, Receivables ranged from a high of $10.1 billion in Q4 2025 to a low of $8.2 billion in Q2 2024.
- A 5-year average of $8.8 billion and a median of $8.7 billion in 2021 frame the typical range for Receivables.
- Across the five-year window, Receivables retreated 10.52% in 2024 and climbed 18.29% in 2025, its largest moves.
- Novartis Ag's Receivables stood at $8.8 billion in 2021, then gained by 2.57% to $9.0 billion in 2022, then dropped by 7.37% to $8.4 billion in 2023, then advanced by 1.93% to $8.5 billion in 2024, then increased by 18.29% to $10.1 billion in 2025.
- According to Business Quant data, Receivables over the past three periods registered $10.1 billion, $9.1 billion, and $8.5 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 21.18 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 17.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 12.48 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 9.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 11.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.08 Bn |
| Jun 30, 2025 | 9.06 Bn |
| Dec 31, 2024 | 8.52 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Dec 31, 2023 | 8.36 Bn |
| Jun 30, 2023 | 9.20 Bn |
| Dec 31, 2022 | 9.02 Bn |
| Jun 30, 2022 | 8.64 Bn |
| Dec 31, 2021 | 8.80 Bn |
| Jun 30, 2021 | 8.40 Bn |
| Dec 31, 2020 | 9.18 Bn |
| Jun 30, 2020 | 7.64 Bn |
| Dec 31, 2019 | 9.47 Bn |
| Jun 30, 2019 | 4.00 Mn |
| Dec 31, 2018 | 10.09 Bn |
| Jun 30, 2018 | 8.80 Bn |
| Dec 31, 2017 | 840.00 Mn |
| Dec 31, 2016 | -162.00 Mn |
| Dec 31, 2015 | -142.00 Mn |
| Jun 30, 2015 | 122.00 |
| Mar 31, 2015 | 83.00 |
| Dec 31, 2013 | 159.00 |
| Mar 31, 2010 | 7,773.00 |
| Dec 31, 2009 | 8,310.00 |
| Sep 30, 2009 | 7,817.00 |
| Jun 30, 2009 | 7,167.00 |
| Mar 31, 2009 | 6,751.00 |